MCE

Pakistan
Pakistan
SEARCH FILTERS
Time filter
Source Type

TFE has partnered with MCE to transition all of its 28 facilities and vineyards in the Napa Valley to 'Deep Green 100% renewable energy'. TFE's investment ensures that all of its usage is matched to vendors that are completely green and thus renewable. TFE's investment complements an ongoing update to its production facilities at Main Street in St. Helena. President and CEO Bob Torkelson commented, "Trinchero Family Estates is proud to be an early adopter for larger wineries in transitioning to clean energy. Our investment supports our sustainability objectives and our commitment to contribute to the community and work productively with our neighbors toward a shared future." As a family-owned winery in the Napa Valley for over 65 years, Trinchero Family Estates has a history of investment in the community and its residents. Accordingly, half of the premiums that TFE invests is used by MCE to fund the development of local renewable energy projects, further benefitting the local community. MCE CEO Dawn Weisz commented on TFE's investment, saying, "We admire the leadership demonstrated by TFE, setting a great example for other businesses to support clean, 100% California renewable energy, which in turn will fund local projects and jobs. The collective impact from all electricity use at TFE's Napa County operations will reduce over 1,200 metric tons of greenhouse gas emissions, which is the EPA equivalent of the carbon sequestered by over 1,175 acres of U.S. forests annually." MCE provides clean power to multiple counties in California and currently serves over 90% of winery customers in Napa. TFE's transition to clean energy complements a variety of environmental programs that are embedded in its business practices and include certifications for sustainably farmed vineyards, a California Green Medal-Sustainable Winegrowing Business Leadership Award, California Wine Institute Certified Sustainable Winegrowing and Napa County Green business certifications. About Trinchero Family Estates Trinchero Family Estates is wholly owned and operated by the Trinchero family, Napa Valley vintners since 1948. The TFE portfolio includes more than 40 brands including Sutter Home, Ménage à Trois, Trinchero Napa Valley, Napa Cellars, Folie à Deux, Terra d'Oro, SeaGlass, and the number one alcohol-removed wine, Fre. TFE also markets and sells a stable of notable brands including Joel Gott Wines, Charles & Charles, Taken Wine Co., and Bandit. TFE's import portfolio includes Angove Wines from Australia; Doña Paula Wines from Argentina; Carmen Wines from Chile; and a spirits portfolio that includes Amador Whiskey Co and Cruz Tequila. Visit www.tfewines.com to learn more. About MCE MCE is a not-for-profit, public electricity provider that gives customers the choice of having 50% to 100% of their electricity supplied from clean, renewable sources such as solar, wind, bioenergy, geothermal, and hydroelectric at competitive rates. MCE provides service to 255,000 California customers in Marin County, Napa County, and the cities of Benicia, El Cerrito, Lafayette, Richmond, San Pablo, and Walnut Creek. By choosing MCE, customers help support new in-state and local renewable energy projects and jobs. For more information about MCE, visit mceCleanEnergy.org


News Article | May 25, 2017
Site: www.prnewswire.co.uk

PharmaMar (MCE:PHM) has announced today a licensing agreement with Eczacıbaşı Group to commercialize the marine-derived anticancer drug Aplidin® (plitidepsin) in Turkey. Under the terms of the agreement, PharmaMar will receive an upfront payment as well as development milestones related to the health approval procedure of Aplidin® in this country. PharmaMar will retain exclusive production rights and will supply the finished product to Eczacıbaşı for commercial use. Aplidin® is PharmaMar´s second most advanced anticancer drug currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma. The Company announced in March 2016 that plitidepsin has shown positive results in a pivotal Phase III clinical trial (ADMYRE) for multiple myeloma[i] and in September 2016, PharmaMar presented to the European Medicines Agency (EMA) the submission of the Marketing Authorization Application (MAA) for this drug in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM)[ii] . "The partnership with Eczacıbaşı will help in the commercialization in Turkey of plitidepsin, developed to tackle hematologic cancer. We are looking forward to working with one of the leading Health Care companies in this country", said Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit. "We are firmly committed to advancing in the development of innovative oncology therapies", he added.


- The test is designed to be used in conjunction with the Procleix® Panther® system, a screening platform utilizing Nucleic Acid Testing (NAT) for fully automated blood testing BARCELONA, Spain, May 23, 2017 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, now provides European countries accepting products with the CE marking with a test to detect the presence of the Zika virus in donated blood. CE marking means a product conforms to relevant legislation for sale in the European economic area. The test is conducted using nucleic acid testing (NAT) on the Procleix® Panther® system automated platform and enables blood banks and donor centers to enhance the safety of their blood supplies. In the U.S., the assay is currently being used under an Investigational New Drug (IND) protocol in response to the U.S. Food and Drug Administration's recommendation to screen all U.S. blood donations for Zika virus. Hologic, a developer, manufacturer and supplier of diagnostic products, received acknowledgement from the FDA for the assay under an IND status in June 2016. In January 2017, Grifols acquired Hologic's business unit engaged in research, development and manufacture of assays and instruments based on NAT technology for blood screening, and became the only vertically integrated provider capable of offering comprehensive solutions to blood and plasma donation centers. This transaction is part of the growth strategy envisaged for the Diagnostic Division and enables Grifols to strengthen its leading position in NAT blood screening safety. "The CE marking of the Procleix Zika virus assay is a further step in our mission to support safer blood donations, the result of our passion for innovation and the role we play as market leaders in transfusion medicine," said Grifols Diagnostic Division President, Carsten Schroeder. NAT offers the capacity to detect the presence of infectious agents in blood and plasma donations, and contributes to increase safety in transfusion diagnostics. About Procleix NAT Solutions The Grifols Procleix portfolio of nucleic acid testing (NAT) products are developed as part of a long-standing partnership between Hologic and Grifols. Today, Procleix systems are used to screen more blood donations around the world than any other NAT blood screening products, and include tests for HIV, hepatitis, West Nile virus and more. The Procleix Panther system automates all aspects of NAT-based blood screening on a single, integrated platform. It eliminates the need for batch processing and combines walk-away freedom with intuitive design for ease of use. The system has received regulatory approvals in countries around the world, and is in development for the U.S. market. About Zika Virus According to the World Health Organization, Zika virus is an emerging mosquito-borne virus that was first identified in rhesus monkeys in Uganda in 1947 and in humans in 1952. Outbreaks of the Zika virus disease have been recorded in Africa, the Americas, Asia and the Pacific. Zika virus is transmitted to people primarily through the bite of an infected mosquito from the Aedes genus, mainly Aedes aegypti, in tropical regions. This is the same mosquito that transmits dengue, chikungunya and yellow fever. However, sexual transmission of Zika virus is also possible. Other modes of transmission such as blood transfusion and perinatal transmission are currently being investigated. In total, 64 countries and territories have reported transmission of Zika virus since January 1, 2007. According to the U.S. Centers for Disease Control and Prevention, local mosquito-borne Zika virus infections have been detected in Florida and Texas, and in US Territories there are reports in the Commonwealth of Puerto Rico, the U.S. Virgin Islands, and American Samoa. About Grifols Grifols is a global healthcare company with more than a 75-year legacy of improving people's health and well-being through the development of protein therapies, hospital pharmacy products and diagnostic technology for clinical use. The company is present in more than 100 countries worldwide, with headquarters located in Barcelona, Spain. Grifols is a leader in plasma collection with a network of more than 170 plasma donation centers in the U.S., and is a leading producer of plasma-derived medicines. As a recognized leader in transfusion medicine, Grifols offers a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks, and transfusion centers. In 2016, sales exceeded 4,000 million euros with approximately 15,000 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D. The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE: GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com. *Product registration and availability vary by country, please contact your local Grifols representative. Procleix is registered trademark of Grifols Worldwide Operations Limited. Panther is registered trademark of Hologic Inc.


News Article | May 25, 2017
Site: www.prnewswire.com

PharmaMar (MCE:PHM) has announced today a licensing agreement with Eczacıbaşı Group to commercialize the marine-derived anticancer drug Aplidin® (plitidepsin) in Turkey. Under the terms of the agreement, PharmaMar will receive an upfront payment as well as development milestones related to the health approval procedure of Aplidin® in this country. PharmaMar will retain exclusive production rights and will supply the finished product to Eczacıbaşı for commercial use. Aplidin® is PharmaMar´s second most advanced anticancer drug currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma. The Company announced in March 2016 that plitidepsin has shown positive results in a pivotal Phase III clinical trial (ADMYRE) for multiple myeloma[i] and in September 2016, PharmaMar presented to the European Medicines Agency (EMA) the submission of the Marketing Authorization Application (MAA) for this drug in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM)[ii] . "The partnership with Eczacıbaşı will help in the commercialization in Turkey of plitidepsin, developed to tackle hematologic cancer. We are looking forward to working with one of the leading Health Care companies in this country", said Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit. "We are firmly committed to advancing in the development of innovative oncology therapies", he added.


News Article | May 25, 2017
Site: globenewswire.com

MACAU, May 26, 2017 (GLOBE NEWSWIRE) -- Melco Resorts Finance Limited, formerly known as MCE Finance Limited (“Melco Resorts Finance”), announces that it has priced its international offering of senior notes due 2025 (the “New Notes”).  Melco Resorts Finance is a wholly-owned subsidiary of Melco Resorts & Entertainment Limited (“Melco”).   The offering consists of US$650 million aggregate principal amount of 4.875% senior notes due 2025. The New Notes were priced at 100%. Melco Resorts Finance intends to use the net proceeds from the offering, together with proceeds in the amount of US$350 million from a drawdown of the revolving credit facility under the amended and restated credit facilities entered into by Melco Crown (Macau) Limited in 2015 and cash on hand, to fund the redemption of all of its outstanding 5.00% Senior Notes due 2021 (the “Existing Notes”). The New Notes are proposed to be senior obligations of Melco Resorts Finance, ranking equally with all of Melco Resorts Finance’s existing and future senior indebtedness. Melco will not be a guarantor of the New Notes. The New Notes are being offered and sold in the United States to qualified institutional buyers pursuant to Rule 144A under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and outside of the United States in reliance on Regulation S under the Securities Act. The New Notes will not be registered under the Securities Act or under the securities laws of any state or other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and any applicable state laws.  Melco Resorts Finance does not intend to register any portion of the offering of the proposed New Notes in the United States. Nothing in this press release constitutes an offer to buy, or a solicitation of an offer to sell, securities in the United States or any other jurisdiction in which such offer or solicitation would be unlawful. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act. This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Melco may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Melco Resorts Finance’s or Melco’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to, (i) growth of the gaming market and visitation in Macau and the Philippines, (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) gaming authority and other governmental approvals and regulations, and (vi) our future business development, results of operations and financial condition. In some cases, forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "anticipate", "target", "aim", "estimate", "intend", "plan", "believe", "potential", "continue", "is/are likely to" or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in Melco’s filings with the SEC. All information provided in this press release is as of the date of this press release, and neither Melco Resorts Finance nor Melco undertakes any duty to update such information, except as required under applicable law. For media enquiry, please contact: Maggie Ma Chief Corporate Communications and Corporate Affairs Officer Tel: +853 8868 3767 or +852 3151 3767 Email: maggiema@melco-resorts.com For investment community, please contact: Ross Dunwoody Vice President, Development and Investor Relations Tel: +853 8868 7575 or +852 2598 3689 Email: rossdunwoody@melco-resorts.com


BARCELONE, Espagne, 23 mai 2017 /PRNewswire/ -- Grifols (MCE : GRF, MCE : GRF.P et NASDAQ : GRFS), un des principaux producteurs mondiaux de médicaments dérivés du plasma, fournit à présent aux pays européens exigeant le marquage CE un test permettant de détecter la présence du virus Zika dans les dons de sang. Le marquage CE indique qu'un produit est conforme à la législation applicable et disponible à la vente dans l'espace économique européen. Le test de l'acide nucléique dans un tube unique (NAT) est réalisé sur la plateforme automatisée Procleix® Panther® et permet aux banques du sang et aux centres de donneurs d'accroître la sécurité de leurs produits sanguins. Aux États-Unis, le test est actuellement utilisé dans le cadre du protocole d'étude des nouveaux médicaments de recherche (NMR) en réponse à la recommandation de la FDA (Food and Drug Administration) de tester tous les dons du sang américains afin de détecter le virus Zika. Hologic, développeur, fabricant et fournisseur de produits de diagnostic, a reçu la confirmation de la FDA que le test serait placé sous le statut de NMR en juin 2016. En janvier 2017, Grifols a fait l'acquisition de l'unité opérationnelle d'Hologic impliquée dans la recherche, le développement et la fabrication de tests et d'instruments basés sur la technologie NAT pour le dépistage sanguin, et est devenu le seul fournisseur dont l'organisation verticale permet de fournir des solutions complètement intégrées aux centres de prélèvement de sang et de plasma. Cette transaction participe à la stratégie de croissance envisagée pour la Division Diagnostic et permet à Grifols de renforcer sa position dominante en matière de sécurité des dépistages sanguins NAT. À propos des solutions NAT Procleix La gamme Grifols Procleix composée de produits basés sur des technologies de Test de l'Acide Nucléique (NAT) est conçue dans le cadre d'un partenariat de longue date conclu entre Hologic et Grifols. Les systèmes Procleix sont aujourd'hui utilisés afin de tester un grand nombre de dons de sang à travers le monde et comprennent des tests pour le VIH, l'hépatite, le virus du Nil occidental, et bien d'autres. À propos du virus Zika D'après l'Organisation mondiale de la santé, le virus Zika est un virus émergent transmis par un moustique, qui a été pour la première fois identifié chez des singes rhésus en Ouganda en 1947, puis chez l'être humain en 1952. Plusieurs épidémies de la maladie virale Zika ont été enregistrées en Afrique, sur le continent américain, en Asie et dans le Pacifique. Le virus Zika se transmet principalement à l'homme via une morsure par un moustique infecté de type Aedes, principalement l'Aedes aegypti dans les régions tropicales. Il s'agit du même moustique qui transmet la dengue, le chikungunya, et la fièvre jaune. Néanmoins, la transmission sexuelle du virus Zika est également possible. D'autres modes de transmission, tels que la transfusion sanguine et la transmission périnatale, font actuellement l'objet d'investigations. Au total, 64 pays et territoires ont rapporté une transmission du virus Zika depuis le 1er janvier 2007. À propos de Grifols  Grifols est une société médicale internationale bénéficiant de plus de 75 années d'expérience dans l'amélioration de la santé et du bien-être des individus, via le développement de protéines thérapeutiques ainsi que de produits de diagnostic et de produits destinés aux pharmacies hospitalières. Présente dans plus de 100 pays à travers le monde, l'entreprise opère depuis son siège social de Barcelone en Espagne. Gérant un réseau de plus de 170 centres de don de plasma aux États-Unis, Grifols compte parmi les leaders de la collecte de plasma et de la fabrication de produits dérivés du plasma. En tant que leader reconnu en médecine transfusionnelle, Grifols propose une gamme complète de solutions en matière de médecine transfusionnelle, d'hémostase, et de réactifs pour tests sérologiques, destiné aux laboratoires cliniques, aux banques du sang, et aux centres de transfusion. ** Dispositifs de Diagnostic In Vitro (IVD), CE (auto déclaration de Conformité CE). Mandataire : Emergo Europe, Molenstraat 15, 2513 BH, The Hague, Pays-Bas. Lire attentivement les instructions figurant dans le manuel d'utilisation du système et sur les notices d'utilisation des réactifs.


News Article | May 23, 2017
Site: www.prnewswire.com

In den USA wird der Testkit derzeit unter einem Investigational New Drug (IND)-Protokoll als Reaktion auf die Empfehlung der US-amerikanischen Food und Drug Administration (FDA), alle U.S.-Blutspenden auf Zika-Viren zu screenen, verwendet. Hologic, ein Entwickler, Hersteller und Lieferant von Diagnoseprodukten, erhielt im Juni 2016 die Anerkennung von der FDA für das Testsystem unter IND-Status. Im Januar 2017 erwarb Grifols die Geschäftseinheit von Hologic, die sich mit Forschung, Entwicklung und Herstellung von Assays und Instrumenten auf Grundlage von NAT-Technologie für Blut-Screening beschäftigte, und wurde so der einzige vertikal-integrierte Anbieter, der in der Lage ist, umfassende Lösungen für Blut-und Plasma-Spendezentren anzubieten. Diese Transaktion ist Teil der Wachstumsstrategie für den Grifols Geschäftsbereich Diagnostic und ermöglicht es dem Unternehmen, seine führende Position im Bereich der NAT-Blut-Screening-Sicherheit zu stärken. Über das Zika Virus Der Weltgesundheitsorganisation WHO zufolge ist das Zika-Virus ein Mücken-Virus, das erstmals im Jahr 1947 bei Rhesus-Affen in Uganda und bei Menschen im Jahr 1952 identifiziert wurde. Ausbrüche der Zika-Viruserkrankung wurden in Afrika, Amerika, Asien und der Pazifik-Region registriert. Das Zika-Virus wird auf Menschen vor allem durch den Biss eines infizierten Moskito der Aedes-Gattung, vor allem Aedes aegypti, in tropischen Regionen übertragen. Dies ist der gleiche Moskito, der Dengue, Chikungunya und Gelbfieber überträgt. Allerdings ist auch die sexuelle Übertragung von Zika Viren möglich. Andere Übertragungsformen wie eine Bluttransfusion und eine perinatale Übertragung werden derzeit erforscht. Seit dem 1. Januar 2007 haben insgesamt 64 Länder und Territorien eine Übertragung von Zika-Viren gemeldet. Laut den U.S. Centers for Disease Control and Prevention sind lokale, von Moskitos übertragene Zika Virusinfektionen in Florida und Texas entdeckt worden, sowie in den US-Territorien Puerto Rico, den US-amerikanischen Jungferninseln und Amerikanisch-Samoa. Das Unternehmen ist in mehr als 100 Ländern der Welt präsent und hat seinen Sitz in Barcelona, Spanien. Grifols ist führend in der Entnahme von Blutplasma, mit einem Netzwerk von über 170 Spendezentren in den USA, und ein führender Hersteller von aus Plasma gewonnenen Arzneimitteln. Als anerkannter Marktführer in der Transfusionsmedizin, bietet Grifols eine umfassende Palette von Transfusionsmedizin-, Hämostase- und Immunoassay-Lösungen für klinische Laboratorien, Blutbanken und Transfusionszentren. Die Klasse-A-Aktien des Unternehmens werden an der spanischen Börse notiert, wo sie Teil des Ibex-35 (MCE:GRF) sind. Die nicht stimmberechtigten Aktien der Klasse B sind am Mercado Continuo gelistet (MCE:GRF.P) und an der US-NASDAQ über ADRs (NASDAQ: GRFS). Weitere Informationen auf www.grifols.com


News Article | May 24, 2017
Site: www.eurekalert.org

Barcelona, May 24, 2017 - Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, now provides European countries accepting products with the CE marking with a test to detect the presence of the Zika virus in donated blood. CE marking means a product conforms to relevant legislation for sale in the European economic area. The test is conducted using nucleic acid testing (NAT) on the Procleix® Panther® system automated platform and enables blood banks and donor centers to enhance the safety of their blood supplies. In the U.S., the assay is currently being used under an Investigational New Drug (IND) protocol in response to the U.S. Food and Drug Administration's recommendation to screen all U.S. blood donations for Zika virus. Hologic, a developer, manufacturer and supplier of diagnostic products, received acknowledgement from the FDA for the assay under an IND status in June 2016. In January 2017, Grifols acquired Hologic's business unit engaged in research, development and manufacture of assays and instruments based on NAT technology for blood screening, and became the only vertically integrated provider capable of offering comprehensive solutions to blood and plasma donation centers. This transaction is part of the growth strategy envisaged for the Diagnostic Division and enables Grifols to strengthen its leading position in NAT blood screening safety. "The CE marking of the Procleix Zika virus assay is a further step in our mission to support safer blood donations, the result of our passion for innovation and the role we play as market leaders in transfusion medicine," said Grifols Diagnostic Division President, Carsten Schroeder. NAT offers the capacity to detect the presence of infectious agents in blood and plasma donations, and contributes to increase safety in transfusion diagnostics. The Grifols Procleix portfolio of nucleic acid testing (NAT) products are developed as part of a long-standing partnership between Hologic and Grifols. Today, Procleix systems are used to screen more blood donations around the world than any other NAT blood screening products, and include tests for HIV, hepatitis, West Nile virus and more. The Procleix Panther system automates all aspects of NAT-based blood screening on a single, integrated platform. It eliminates the need for batch processing and combines walk-away freedom with intuitive design for ease of use. The system has received regulatory approvals in countries around the world, and is in development for the U.S. market. According to the World Health Organization, Zika virus is an emerging mosquito-borne virus that was first identified in rhesus monkeys in Uganda in 1947 and in humans in 1952. Outbreaks of the Zika virus disease have been recorded in Africa, the Americas, Asia and the Pacific. Zika virus is transmitted to people primarily through the bite of an infected mosquito from the Aedes genus, mainly Aedes aegypti, in tropical regions. This is the same mosquito that transmits dengue, chikungunya and yellow fever. However, sexual transmission of Zika virus is also possible. Other modes of transmission such as blood transfusion and perinatal transmission are currently being investigated. In total, 64 countries and territories have reported transmission of Zika virus since January 1, 2007. According to the U.S. Centers for Disease Control and Prevention, local mosquito-borne Zika virus infections have been detected in Florida and Texas, and in US Territories there are reports in the Commonwealth of Puerto Rico, the U.S. Virgin Islands, and American Samoa. Grifols is a global healthcare company with more than a 75-year legacy of improving people's health and well-being through the development of protein therapies, hospital pharmacy products and diagnostic technology for clinical use. The company is present in more than 100 countries worldwide, with headquarters located in Barcelona, Spain. Grifols is a leader in plasma collection with a network of more than 170 plasma donation centers in the U.S., and is a leading producer of plasma-derived medicines. As a recognized leader in transfusion medicine, Grifols offers a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks, and transfusion centers. In 2016, sales exceeded 4,000 million euros with approximately 15,000 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D. The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE: GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit http://www. . *Product registration and availability vary by country, please contact your local Grifols representative. Panther is registered trademark of Hologic Inc.


News Article | May 24, 2017
Site: www.prnewswire.com

ARLINGTON, Va., May 24, 2017 /PRNewswire-USNewswire/ -- Today, American Trucking Associations announced registration is open for the 2017 ATA Management Conference & Exhibition – MCE 2017 – to be held this October 21-24 in Orlando, Florida. "Each year, MCE gives ATA the chance to...


Babesia is caused by microscopic parasites and is transmitted primarily through tick bites. However, as the disease is spread during ticks' young nymph stage, many patients are unaware of a tick encounter. There may be no symptoms, or those affected may experience flu-like symptoms. The disease destroys red blood cells and can lead to hemolytic anemia (jaundice and hemoglobinuria). Individuals with compromised immune systems may experience more severe complications. Although widespread, the main concentrations of the disease are found in the Northeastern and Midwestern portions of the U.S., according to the Center for Disease Control (CDC). The latest data from the CDC show more than 1,700 people were affected by Babesia in 2014 with highest concentrations in Massachusetts, New York, Connecticut, Rhode Island, New Jersey, Maine, New Hampshire, Wisconsin, and Minnesota. The Procleix Babesia assay is designed to be a qualitative in vitro nucleic acid screening test for the direct detection of the Babesia parasite in specimens from human blood donors on the fully automated Procleix Panther system platform. This test, developed by Grifols Diagnostic Solutions, Inc., is designed to enable participating blood banks and donor centers in the U.S. to test donations to further safety of their blood supplies. "The availability of the assay under the IND protocol and in collaboration with the FDA marks another important milestone for Grifols," said Grifols Diagnostic Division President, Carsten Schroeder. "As leaders in the NAT blood screening market, we remain committed to preserve the safety of blood donations from the presence of unwanted pathogens. The Procleix Babesia assay will add to our growing portfolio and has been expressly designed to address the needs of the blood banking community." Currently, the majority of blood donations in the U.S. are being tested with the Procleix Zika virus assay (on the Procleix Panther system), released in June 2016 under an IND study. About Procleix NAT Solutions Today, Procleix systems are used to screen more blood donations around the world than any other NAT blood screening products, and include tests for HIV, hepatitis (A, B, C and E) viruses, West Nile virus and more. The Procleix Panther system automates all aspects of NAT-based blood screening on a single, integrated platform. It eliminates the need for batch processing and combines walk-away freedom with intuitive design for ease of use. The system has received regulatory approvals in countries around the world, and is in development for the U.S. market. About Grifols Grifols is a global healthcare company with more than a 75-year legacy of improving people's health and well-being through the development of protein therapies, hospital pharmacy products and diagnostic technology for clinical use. The company is present in more than 100 countries worldwide, with headquarters located in Barcelona, Spain. Grifols is a leader in plasma collection with a network of more than 170 plasma donation centers in the U.S., and is a leading producer of plasma-derived medicines. As a recognized leader in transfusion medicine, Grifols offers a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks, and transfusion centers. In 2016, sales exceeded 4,000 million euros with approximately 15,000 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D. The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE: GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com. Procleix is a registered trademark of Grifols Worldwide Operations Limited. Panther is a registered trademark of Hologic, Inc. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/investigational-new-drug-application-is-now-effective-for-babesia-screening-in-blood-donations-using-grifols-procleix-panther-system-in-the-us-300454212.html

Loading MCE collaborators
Loading MCE collaborators